Successful biotech investors keep a close eye on the calendar. Regulatory decisions and clinical trial results move this sector, so it's important to stay on top of these events whenever possible. To help readers, I've put together another list of biotech catalyst events for the remainder of this year and the beginning of 2005. This calendar builds upon a similar list I put together in September. Judging by the large volume of email I received after that column was published, a biotech calendar is something a lot of people find extremely valuable. In the interest of brevity, I've kept descriptions here to a minimum, but I'll likely cover many of these events in more detail in the future.
FDA Approval Decision Dates:
Biogen Idec (BIIB) and Elan (ELN): Antegren, multiple sclerosis, Nov. 25;
OSI Pharmaceuticals (OSIP) and Genentech (DNA): Tarceva, non-small-cell lung cancer, Jan. 30, 2005. (OSI has said it expects approval decision to come earlier than Jan. 30, but the company is not any more specific.);
American Pharmaceutical Partners (APPX): Abraxane, breast cancer, Jan. 8, 2005;